These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 12443837)

  • 1. Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women.
    Voipio SK; Komi J; Kangas L; Halonen K; DeGregorio MW; Erkkola RU
    Maturitas; 2002 Nov; 43(3):207-14. PubMed ID: 12443837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial.
    Rutanen EM; Heikkinen J; Halonen K; Komi J; Lammintausta R; Ylikorkala O
    Menopause; 2003; 10(5):433-9. PubMed ID: 14501605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women.
    Komi J; Lankinen KS; Härkönen P; DeGregorio MW; Voipio S; Kivinen S; Tuimala R; Vihtamäki T; Vihko K; Ylikorkala O; Erkkola R
    Menopause; 2005 Mar; 12(2):202-9. PubMed ID: 15772568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus.
    Simon JA; Lin VH; Radovich C; Bachmann GA;
    Menopause; 2013 Apr; 20(4):418-27. PubMed ID: 23096251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogenic effects of toremifene and tamoxifen in postmenopausal breast cancer patients.
    Ellmén J; Hakulinen P; Partanen A; Hayes DF
    Breast Cancer Res Treat; 2003 Nov; 82(2):103-11. PubMed ID: 14692654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maturation of vaginal and endometrial epithelium in postmenopausal breast cancer patients receiving long-term tamoxifen.
    Lahti E; Vuopala S; Kauppila A; Blanco G; Ruokonen A; Laatikainen T
    Gynecol Oncol; 1994 Dec; 55(3 Pt 1):410-4. PubMed ID: 7835781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial.
    Archer DF; Goldstein SR; Simon JA; Waldbaum AS; Sussman SA; Altomare C; Zhu J; Yoshida Y; Schaffer S; Soulban G
    Menopause; 2019 Jan; 26(6):611-621. PubMed ID: 30694917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overall Safety of Ospemifene in Postmenopausal Women from Placebo-Controlled Phase 2 and 3 Trials.
    Simon JA; Altomare C; Cort S; Jiang W; Pinkerton JV
    J Womens Health (Larchmt); 2018 Jan; 27(1):14-23. PubMed ID: 29064335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial.
    Portman D; Palacios S; Nappi RE; Mueck AO
    Maturitas; 2014 Jun; 78(2):91-8. PubMed ID: 24679891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaginal, endometrial, and reproductive hormone findings: randomized, placebo-controlled trial of black cohosh, multibotanical herbs, and dietary soy for vasomotor symptoms: the Herbal Alternatives for Menopause (HALT) Study.
    Reed SD; Newton KM; LaCroix AZ; Grothaus LC; Grieco VS; Ehrlich K
    Menopause; 2008; 15(1):51-8. PubMed ID: 18257142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue selectivity of ospemifene: pharmacologic profile and clinical implications.
    Kangas L; Unkila M
    Steroids; 2013 Dec; 78(12-13):1273-80. PubMed ID: 24055829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endometrial safety of ospemifene: results of the phase 2/3 clinical development program.
    Constantine GD; Goldstein SR; Archer DF
    Menopause; 2015 Jan; 22(1):36-43. PubMed ID: 24977459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of RU16117, an orally active weak oestrogenic compound, in postmenopausal women.
    Faure N; Labrie F; Olivier G; Tremblay M; Cloutier D; Lemay A; Ferland L; Azadian-Boulanger G; Bouton MM; Husson JM; Raynaud JP
    Maturitas; 1980 Jul; 2(2):155-68. PubMed ID: 6782429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause.
    Wurz GT; Kao CJ; DeGregorio MW
    Clin Interv Aging; 2014; 9():1939-50. PubMed ID: 25419123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy.
    Portman DJ; Bachmann GA; Simon JA;
    Menopause; 2013 Jun; 20(6):623-30. PubMed ID: 23361170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study.
    Bachmann GA; Komi JO;
    Menopause; 2010; 17(3):480-6. PubMed ID: 20032798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of hepatic impact of oral and vaginal administration of ethinyl estradiol.
    Goebelsmann U; Mashchak CA; Mishell DR
    Am J Obstet Gynecol; 1985 Apr; 151(7):868-77. PubMed ID: 3920910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the phytoestrogen genistein on hot flushes, endometrium, and vaginal epithelium in postmenopausal women: a 2-year randomized, double-blind, placebo-controlled study.
    D'Anna R; Cannata ML; Marini H; Atteritano M; Cancellieri F; Corrado F; Triolo O; Rizzo P; Russo S; Gaudio A; Frisina N; Bitto A; Polito F; Minutoli L; Altavilla D; Adamo EB; Squadrito F
    Menopause; 2009; 16(2):301-6. PubMed ID: 19034051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ospemifene for the treatment of dyspareunia in postmenopausal women.
    Paton DM
    Drugs Today (Barc); 2014 May; 50(5):357-64. PubMed ID: 24918836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does dong quai have estrogenic effects in postmenopausal women? A double-blind, placebo-controlled trial.
    Hirata JD; Swiersz LM; Zell B; Small R; Ettinger B
    Fertil Steril; 1997 Dec; 68(6):981-6. PubMed ID: 9418683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.